Rationale for Combinatory Chronic Lymphocytic Leukaemia Treatment Paradigms in the Era of the B-Cell Receptor Pathway and Anti-Apoptotic Inhibitors: How Do We Mix, Match, and Move Forward?

British Journal of Haematology - United Kingdom
doi 10.1111/bjh.14446
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

Targeting the B Cell Receptor Pathway in Chronic Lymphocytic Leukemia

Leukemia and Lymphoma
Cancer ResearchOncologyHematology
2012English

Dietary Recommendations: How Do We Move Forward?

British Journal of Nutrition
MedicineNutritionDietetics
1990English

Chronic Lymphocytic Leukaemia Genomics and the Precision Medicine Era

British Journal of Haematology
Hematology
2017English

Enhancing Reproducibility in Cancer Drug Screening: How Do We Move Forward?

Cancer Research
Cancer ResearchOncology
2014English

Chronic Lymphocytic Leukaemia: The Role of T Cells in a B Cell Disease

British Journal of Haematology
Hematology
2019English

Venetoclax Is an Option in B‐cell Prolymphocytic Leukaemia Following Progression on B‐cell Receptor Pathway Inhibitors

British Journal of Haematology
Hematology
2019English

Treatment Options for High-Risk Chronic Lymphocytic Leukaemia

Therapeutic Advances in Hematology
Hematology
2011English

Signal-Dependent and Signal-Independent Functions of the B-Cell Receptor in Chronic Lymphocytic Leukemia

Haematologica
Hematology
2014English

Chronic Lymphocytic Leukaemia

Nature Reviews Disease Primers
Medicine
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy